Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01JLO
|
||||
| Former ID |
DIB010336
|
||||
| Drug Name |
Tat-NR2B9c
|
||||
| Synonyms |
NA-1; NA-1); PSD-95 inhibitor (stroke), NoNO/Arbor Vita; NMDAR NR2 domain-binding protein + HIV-1 Tat protein (Stroke), NoNO/Arbor Vita
|
||||
| Indication | Cerebrovascular ischaemia [ICD9: 434.91; ICD10:I61-I63] | Phase 3 | [1], [2], [3] | ||
| Company |
Nono inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | Presynaptic density protein 95 | Target Info | Inhibitor | [1], [2], [3] | |
| KEGG Pathway | Hippo signaling pathway | ||||
| Glutamatergic synapse | |||||
| Huntington's disease | |||||
| Cocaine addiction | |||||
| PANTHER Pathway | Huntington disease | ||||
| Pathway Interaction Database | ErbB4 signaling events | ||||
| Reactome | Trafficking of AMPA receptors | ||||
| Unblocking of NMDA receptor, glutamate binding and activation | |||||
| CREB phosphorylation through the activation of CaMKII | |||||
| Ras activation uopn Ca2+ infux through NMDA receptor | |||||
| RHO GTPases activate CIT | |||||
| RAF/MAP kinase cascade | |||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | ||||
| L1CAM interactions | |||||
| References | |||||
| REF 1 | Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science. 1999 Jun 11;284(5421):1845-8. | ||||
| REF 2 | Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012 Feb 29;483(7388):213-7. | ||||
| REF 3 | Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science. 1995 Sep 22;269(5231):1737-40. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.